CareTrust REIT Finalizes $502.8M Forward Sale Equity Offering
summarizeSummary
CareTrust REIT finalized a $502.8 million forward sale equity offering, selling 12.5 million shares at $40.225 each, with an option for additional shares. This capital raise is expected to support the company's ongoing acquisition strategy.
check_boxKey Events
-
Forward Sale Equity Offering Finalized
CareTrust REIT entered into an underwriting agreement and forward sale agreements for 12,500,000 shares of common stock at $40.225 per share, with an option for underwriters to purchase an additional 1,875,000 shares.
-
Substantial Capital Raise
The offering is expected to generate gross proceeds of approximately $502.8 million, potentially increasing to $578.3 million if the underwriters' option is fully exercised. This represents a significant capital infusion for the company.
-
Pricing and Closing Confirmed
The offering was priced at $40.225 per share, a modest discount to the current market price of $41.49. The closing of the offering occurred on May 20, 2026, formalizing the transaction.
-
Strategic Use of Proceeds
The capital raise follows strong Q1 2026 financial results and over $637 million in recent acquisitions, suggesting the proceeds will be used to fund future investments and growth initiatives.
auto_awesomeAnalysis
CareTrust REIT has finalized a significant forward sale equity offering, securing $502.8 million through the sale of 12.5 million shares, with an option for an additional $75.5 million. This capital raise, priced at $40.225 per share (a modest discount to the current market price), formalizes the terms and confirms the closing of an offering previously announced. The company has recently reported strong financial results and over $637 million in acquisitions, indicating this capital is likely intended to fund further growth and investments, strengthening its financial position.
At the time of this filing, CTRE was trading at $41.49 on NYSE in the Real Estate & Construction sector, with a market capitalization of approximately $9.8B. The 52-week trading range was $27.81 to $43.08. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.